Zacks Investment Research on MSN
Is Adicet Bio (ACET) stock outpacing its medical peers this year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Adicet Bio, Inc. (ACET) been one of those stocks this year?
This oncology biotech advancing targeted therapies reported a notable insider sale amid ongoing clinical-stage development.
8don MSN
Bio-Techne is a top S&P 500 stock. Germany’s Merck is paying a 24% premium for the company
Bio-Techne stock jumps, with Germany’s Merck KGaA buying the company at a 24% premium.
Gossamer Bio’s latest analyst update leaves the model fair value unchanged at US$4.46 per share and highlights an underweight stance, anchored by a sharply lower US$0.28 price target from some on the ...
On June 25, 2026, investors tracked deal progress as Bio-Techne shares responded to the proposed buyout terms.
Shares of Nuvation Bio (NYSE: NUVB) were skyrocketing 15.7% higher as of 11:20 a.m. ET on Tuesday. The big jump came after two positive developments for the cancer-focused drugmaker. Which news ...
Passage Bio, Inc. announced a reverse stock split of its common stock at a ratio of 1-for-20, effective July 14, 2025, in order to meet Nasdaq's minimum bid price requirement of $1.00 per share. The ...
On Thursday, Tevogen Bio Holdings Inc. (NASDAQ:TVGN) announced its top-line revenue forecast for its oncology pipeline, projecting $1 billion in revenue in its launch year and a cumulative 5-year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results